Veru Stock News

MIAMI, March 02, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, t

Veru (VERU) delivered earnings and revenue surprises of 50.00% and 37.56%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Veru Inc (NASDAQ: VERU) will start testing VERU-111 in the registrational Phase 3 study in hospitalized patients who have COVID-19 virus infection and are at high risk for Acute Respiratory Distre

--TADFIN™, Tadalafil 5mg and Finasteride 5mg formulated capsule, for daily oral dosing to improve compliance-- --Administration of Tadalafil and Finasteride is more effective than Finasteride alone

Community Health Systems (NYSE: CYH) shares are trading higher after the company reported better-than-expected fourth-quarter sales results. Community Health Systems is the largest publicly owned hosp

Veru Inc (NASDAQ: VERU) priced its underwritten public offering of 6.5 million shares at $15.50 per share, with gross proceeds of approximately $100 million. Underwriters have an option to purchas

MIAMI, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, an

MIAMI, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, an

Veru, Inc. (VERU) CEO Mitchell Steiner on Q1 2021 Results - Earnings Call Transcript

Female Health Company The (VERU) delivered earnings and revenue surprises of 50.00% and 37.56%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the

Shares of Veru (NASDAQ:VERU) moved higher by 17.6% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 60.00% year over year to ($0.02), which beat t

--Q1 FY21 Net Revenues and Gross Profit of $15M and $11M, Respectively, Achieve New Historical Highs for Second Consecutive Quarter-- --Late Clinical Stage Oncology Drug Pipeline Focused on Prostate a

Analysts are excited about the potential of the biotech's experimental COVID-19 treatment.

Dr. Mitchell Steiner, chief executive of drugmaker Veru, said a Phase 2 trial of VERU-111 showed an 82% relative reduction in Covid-19 patient mortality versus placebo.

Veru CEO Dr. Mitchell Steiner explained how VERU-111, a prostate cancer drug developed by the biotech company, could be used as an anti-inflammatory and antiviral treatment to help patients diagnosed